FDA Welcomes Sotagliflozin Data for Heart Failure in Diabetes
The FDA says data from two pivotal trials can be used to help support a new drug application for the dual SGLT1/2 inhibitor, according to a statement by Lexicon Pharmaceuticals. Medscape Medical News